Metastatic-directed therapy using PSMA-PET/CT at PSA relapse

The side effects of androgen deprivation therapy (ADT) as general treatment against prostate cancer are known to impair quality of life. However, the optimal onset of ADT at PSA relapse is unknown, especially in patients with normal testosterone. In our case a limited PSMA avid lymph node was detect...

Descripción completa

Detalles Bibliográficos
Autores principales: Lilleby, Oscar, Hernes, Eivor, Lilleby, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704039/
https://www.ncbi.nlm.nih.gov/pubmed/31453108
http://dx.doi.org/10.1016/j.eucr.2019.100992
_version_ 1783445422132428800
author Lilleby, Oscar
Hernes, Eivor
Lilleby, Wolfgang
author_facet Lilleby, Oscar
Hernes, Eivor
Lilleby, Wolfgang
author_sort Lilleby, Oscar
collection PubMed
description The side effects of androgen deprivation therapy (ADT) as general treatment against prostate cancer are known to impair quality of life. However, the optimal onset of ADT at PSA relapse is unknown, especially in patients with normal testosterone. In our case a limited PSMA avid lymph node was detected on PET/CT. Our case highlights the importance of metastasis-directed therapy balancing general versus tailored treatment in the decision making in the era of advanced molecular imaging. By using PSMA-PET/CT and radiation we were able to pinpoint the metastasis prolonging the ADT-free survival, thus sparing the patient the side-effects of continuous ADT.
format Online
Article
Text
id pubmed-6704039
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-67040392019-08-26 Metastatic-directed therapy using PSMA-PET/CT at PSA relapse Lilleby, Oscar Hernes, Eivor Lilleby, Wolfgang Urol Case Rep Oncology The side effects of androgen deprivation therapy (ADT) as general treatment against prostate cancer are known to impair quality of life. However, the optimal onset of ADT at PSA relapse is unknown, especially in patients with normal testosterone. In our case a limited PSMA avid lymph node was detected on PET/CT. Our case highlights the importance of metastasis-directed therapy balancing general versus tailored treatment in the decision making in the era of advanced molecular imaging. By using PSMA-PET/CT and radiation we were able to pinpoint the metastasis prolonging the ADT-free survival, thus sparing the patient the side-effects of continuous ADT. Elsevier 2019-08-09 /pmc/articles/PMC6704039/ /pubmed/31453108 http://dx.doi.org/10.1016/j.eucr.2019.100992 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Oncology
Lilleby, Oscar
Hernes, Eivor
Lilleby, Wolfgang
Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
title Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
title_full Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
title_fullStr Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
title_full_unstemmed Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
title_short Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
title_sort metastatic-directed therapy using psma-pet/ct at psa relapse
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704039/
https://www.ncbi.nlm.nih.gov/pubmed/31453108
http://dx.doi.org/10.1016/j.eucr.2019.100992
work_keys_str_mv AT lillebyoscar metastaticdirectedtherapyusingpsmapetctatpsarelapse
AT herneseivor metastaticdirectedtherapyusingpsmapetctatpsarelapse
AT lillebywolfgang metastaticdirectedtherapyusingpsmapetctatpsarelapse

Ejemplares similares